Novavax (NVAX) Common Equity (2010 - 2026)

Novavax's Common Equity history runs 17 years deep, the most recent figure standing at -$144.8 million for Q1 2026.

• On a quarterly basis, Common Equity fell 91.38% year-over-year to -$144.8 million in Q1 2026; TTM through Mar 2026 was -$144.8 million, a 91.38% decrease from a year earlier, with the FY2025 full-year figure at -$127.8 million, up 79.52% from the prior year.
• Common Equity eased to -$144.8 million in Q1 2026 per NVAX's latest filing, from -$127.8 million in the prior quarter.
• Across five years, Common Equity topped out at $65.3 million in Q1 2022 and bottomed at -$895.6 million in Q1 2023.
• The 5-year median for Common Equity is -$526.4 million (2024), against an average of -$442.0 million.
• Across the five-year window, Common Equity slumped 1470.98% in 2023 and jumped 108.72% in 2025, its largest moves.
• Year by year, Common Equity stood at -$634.1 million in 2022, then declined by 13.07% to -$716.9 million in 2023, then increased by 12.98% to -$623.8 million in 2024, then soared by 79.52% to -$127.8 million in 2025, then decreased by 13.31% to -$144.8 million in 2026.
• Per Business Quant, the three latest NVAX Common Equity figures stand at -$144.8 million (Q1 2026), -$127.8 million (Q4 2025), and -$156.7 million (Q3 2025).